NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door to standard chemotherapy for patients whose cancers have become resistant ...
Backed by more than 30 peer-reviewed human clinical studies supporting endogenous antioxidant activity, cellular ...
Researchers have discovered that the transcription factor NRF2 plays a major role in herpes infection and thus is an effective target for restricting viral infection. The herpes simplex virus (HSV) is ...
INrf2 tethering of the transcription factor Nrf2 in the cytosol prevents Nrf2 activation of antioxidant response element (ARE) mediated gene expression. This investigation was undertaken to determine ...
NRF2 is just one of thousands of critical proteins in the cell, but it is one that we now know a lot about. Once any molecule achieves a certain level of celebrity status, it tends to acquire a ...
Sapanisertib is a dual mTORC 1/2 inhibitor that targets a key survival mechanism in KEAP1/NRF2-mutated tumor cells. The Food and Drug Administration (FDA) has granted Fast Track designation to ...
SALT LAKE CITY, Nov. 29, 2023 (GLOBE NEWSWIRE) -- LifeVantage Corporation (Nasdaq:LFVN), a leading health and wellness company with products designed to activate optimal health processes, today ...
NFE2-related factor 2 (NRF2) is a transcription factor that integrates cellular stress signals and responds by directing various transcriptional programmes. NRF2 was a somewhat esoteric protein little ...
Vividion Therapeutics Inc. has disclosed VVD-065, a novel, first-in-class, allosteric molecular glue of the KEAP1-CUL3 E3-ligase complex, for the potential treatment of NRF2-activated cancers. NRF2 ...
A new publication from CorriXR Therapeutics, an oncology focused biotherapeutics company developing genetic medicines to overcome drug resistance in solid tumors, shows that its novel CRISPR-directed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results